|Clinical and Regulatory|
This event is set for a specific date and makes planning easier. However, specific dates may change.
|Disease and Treatment|
|Indication:||post-surgical ocular pain|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|Co. Name:||Ocular Therapeutix|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
PDUFA target action date of July 24, 2016 for the NDA for DEXTENZA™ for the treatment of post-surgical ocular pain